Meredith, Ian T2; Verheye, Stefan3; Weissman, Neil J3; Barragan, Paul3; Scott, Douglas3; Valdés Chávarri, Mariano3; West, Nick E J3; Kelbæk, Henning Skov4; Whitbourn, Robert3; Walters, Darren L3; Kubica, Jacek3; Thuesen, Leif5; Masotti, Monica3; Banning, Adrian3; Sjögren, Iwar3; Stables, Rod H3; Allocco, Dominic J3; Dawkins, Keith D3
1 Department of Clinical Medicine - The Department of Cardiological Medicine B, Department of Clinical Medicine, Health, Aarhus University2 MonashHeart, Clayton, Victoria, Australia. email@example.com unknown4 Institut for Klinisk Medicin5 The Department of Cardiological Medicine B, Faculty of Health Sciences, Aarhus University, Aarhus University
a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent
The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) compared with the durable polymer PROMUS Element (PE) EES. The current analysis describes the six-month IVUS and clinical results through two years from the EVOLVE FHU trial.
Eurointervention : Journal of Europcr in Collaboration With the Working Group on Interventional Cardiology of the European Society of Cardiology, 2013, Vol 9, Issue 3, p. 308-15